INGN has been the topic of several other research reports. Needham & Company LLC raised shares of Smart Global from a hold rating to a buy rating and set a $32.00 target price on the stock in a research note on Friday, June 28th. Stifel Nicolaus raised shares of Protagonist Therapeutics from a hold rating to a buy rating and lifted their price objective for the stock from $11.00 to $17.00 in a research note on Wednesday, May 8th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of from GBX 385 ($5.03) to GBX 480 ($6.27) and gave the stock an overweight rating in a research note on Wednesday, July 3rd. Three analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $117.60.
INGN stock opened at $63.18 on Friday. The firm has a market cap of $1.39 billion, a PE ratio of 27.47, a PEG ratio of 2.43 and a beta of 1.45. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.70 and a current ratio of 7.35. The business has a 50-day moving average price of $64.69. Inogen has a fifty-two week low of $56.83 and a fifty-two week high of $287.79.
Large investors have recently modified their holdings of the company. Marshall Wace LLP boosted its stake in shares of Inogen by 180.2% in the 1st quarter. Marshall Wace LLP now owns 55,580 shares of the medical technology company’s stock valued at $5,301,000 after purchasing an additional 35,747 shares in the last quarter. Geode Capital Management LLC lifted its position in Inogen by 8.6% during the 4th quarter. Geode Capital Management LLC now owns 205,160 shares of the medical technology company’s stock worth $25,474,000 after buying an additional 16,183 shares in the last quarter. Legal & General Group Plc lifted its position in Inogen by 3.9% during the 4th quarter. Legal & General Group Plc now owns 17,963 shares of the medical technology company’s stock worth $2,230,000 after buying an additional 668 shares in the last quarter. Renaissance Group LLC acquired a new position in Inogen during the 1st quarter worth about $428,000. Finally, MetLife Investment Advisors LLC lifted its position in Inogen by 52.3% during the 4th quarter. MetLife Investment Advisors LLC now owns 18,341 shares of the medical technology company’s stock worth $2,277,000 after buying an additional 6,302 shares in the last quarter. Institutional investors own 98.63% of the company’s stock.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Read More: Forex
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.